WO2011024029A1 - Formes posologiques de combinaison de cinnarizine et de diménhydrinate à désintégration rapide - Google Patents

Formes posologiques de combinaison de cinnarizine et de diménhydrinate à désintégration rapide Download PDF

Info

Publication number
WO2011024029A1
WO2011024029A1 PCT/IB2009/053702 IB2009053702W WO2011024029A1 WO 2011024029 A1 WO2011024029 A1 WO 2011024029A1 IB 2009053702 W IB2009053702 W IB 2009053702W WO 2011024029 A1 WO2011024029 A1 WO 2011024029A1
Authority
WO
WIPO (PCT)
Prior art keywords
cinnarizine
dimenhydrinate
combination
fast
tablet
Prior art date
Application number
PCT/IB2009/053702
Other languages
English (en)
Inventor
Farhad Farshi
Serdar Soylemez
Fikret Koc
Original Assignee
Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi filed Critical Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi
Priority to PCT/IB2009/053702 priority Critical patent/WO2011024029A1/fr
Publication of WO2011024029A1 publication Critical patent/WO2011024029A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates

Definitions

  • the present invention is related to fast dissolving or fast disintegrating dosage forms of combination of cinnarizine and dimenhydrinate.
  • Cinnarizine is an antihistamine and vasodilator and is delineated in patent of US
  • Dimenhydrinate is an antihistamine used as an antiemetic and against travel sickness and is described in patents of US 2,499,058 or US 2,534,813.
  • a compound preparation for dizziness comprising cinnarizine and dimenhydrinate is embraced by EP 1622622 and literature for example ; 'Supportive therapy with dimenhydrinate in combination with cinnarizine in vertigo' THERAPIEWOCHE 1996 GERMANY, Bd. 46, Nr. 3, 1996, Miracle 175.
  • the present invention provides a fast disintegrating dosage forms of cinnarizine and dimenhydrinate.
  • Fast disintegrating dosage forms include an effective amount of cinnarizine or a pharmaceutically acceptable salt thereof, and an effective amount of dimenhydrinate or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient.
  • pharmaceutical formulations are disintegrated in less than three minutes in oral cavity . More preferably, the pharmaceutical formulations are disintegrated in a oral cavity in less than two minutes and most preferably the pharmaceutical formulations are disintegrated in oral cavity in less than one minute.
  • One subject of the present invention is the use of fast disintegrating formulations of combination of cinnarizine and dimenhydrinate or their pharmaceutically acceptable salts for the treatment, amelioration or prevention of dizziness, including vertigo and Meniere's disorder.
  • the fast disintegrating formulations are used in treating all forms of vertigo. Vertigo which cannot be clearly diagnosed is included.
  • the pharmaceutical formulation is in a dosage form may be, but not limited to,rapidly disintegrating tablets, lingual strips, sublingual tablets, lyophilized wafers, granulated particles, sublingual strips, spray and whatsoever.
  • a fast-disintegrating tablets may have many numerous shapes, such as dish-like , ellipsoid , rods, granules, blocks, cubes with rounded edges, or any other shape suitable for pharmaceutical administration.
  • Cinnarizine and dimenhydrinate can be administered in pharmaceutically acceptable doses.
  • fast disintegrating or fast dissolving dosage form may include one or more pharmaceutically acceptable excipients, carriers, or diluents.
  • surfactants, diluents, sweeteners, disintegrants, binders, lubricants, glidants, colorants, flavors and mixtures thereof can be used.
  • Acceptable excipients are, but not limited to, calcium sulfate, starch, mannitol,
  • kaolin sorbitol, xylitol, sodium chloride, sodium bicarbonate, citric acid, powdered cellulose derivatives, microcrystalline cellulose, pullulan, silicified microcrystalline cellulose, ammonium bicarbonate, carrageenan, carbohydrates such as PharmaburstTM, magnesium carbonate, tribasic calcium phosphate, calcium sulfate, magnesium oxide, poloxamer,gums, hydroxypropyl methylcellulose, gelatin, mixtures thereof, and the like .
  • Diluents may be, but not limited to, mannitol, sorbitol, xylitol, microcrystalline
  • cellulose silicified microcrystalline cellulose , hydroxypropyl methylcellulose, hydroxypropyl cellulose , pullulan and fast dissolving carbohydrates such as
  • Glidants may be, but not limited to, silicon dioxide, colloidal silicon dioxide, calcium silicate, magnesium silicate, magnesium trisilicate, talc, starch , mixtures thereof or whatsoever.
  • Binders are, but not limited to, sodium alginate, cellulose, methylcellulose, ethyl- cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, sodium car- boxymethyl cellulose, polypropylpyrrolidone, polyvinylprrolidone, gelatin, polyethylene glycol, starch, pre-gelatinized starch, sugars, trehalose,
  • Lubricants may be, but not limited to, calcium stearate, glyceryl monostearate,
  • glyceryl behenate glyceryl palmitostearate, hydrogenated vegetable oil, light mineral oil, magnesium stearate, mineral oil, polyethylene glycol, poloxamer, sodium benzoate, sodium lauryl sulfate, sodium stearyl fumarate, stearic acid, talc, zinc stearate, mixtures thereof or whatsoever .
  • Disintegrants are, but not limited to, sodium starch glycolate, sodium carboxymethyl cellulose, calcium carboxymethyl cellulose, croscarmellose sodium, crospovidone, alginic acid, chitosan, methyl cellulose, microcrystalline cellulose, powdered cellulose, lower alkylsubstituted hydroxypropyl cellulose, polacrilin potassium, starch, prege- latinized starch, sodium alginate, mixtures thereof or whatsoever.
  • Flavors are, but not limited to, cinnamon oil,essence of apple, essence of pear,
  • Sweeteners are but not limited to, corn syrup, dextrose, invert sugar, fructose,
  • saccharin aspartame, acesulfame-K, Stevia rebaudiana, sucralose, sorbitol, mannitol, zylitol, mixtures thereof and the like.
  • the fast-disintegrating or fast dissolving dosage form of combination of cinnarizine and dimenhydrinate is a solid dosage form that does not require water for swallowing.
  • These fast disintegrating or fastdissolving dosage forms are typically tablets and thin films that dissolve or disperse rapidly when in contact with saliva.
  • compositions of the present invention can be prepared through using pharmaceutical technologies including, but not limited to, spray drying, freeze-drying, heat molding,tablet molding, sublimation, consumable thin film manufacture and tablet .
  • Fast dissolving and/or fast disintegrating dosage forms of combination of cinnarizine and dimenhydrinate are selected from the group consisting of lingual strips, sublingual strips, oral mists, rapidly disintegrating tablets, lyophilized wafers, granulated particles and gums.
  • Cinnarizine and dimenhydrinate can be in microparticulate form with one or more excipients. Microparticulation can also be usedas taste-masking method.
  • microencapsulation methods can also be applied to cinnarizine and dimenhydrinate.
  • Excipients useful for microencapsulation, are, but not limited to, methylcellulose phthalate; hydroxypropylmethylcellulose phthalate; hy- droxypropylmethylcellulose succinate; hydroxyethyl-ethylcellulose phthalate, cellulose aceto succinate, polylactic acid, polyglycolic acid, polyvinyl alcohol, cellulose acetate phthalate, ethyl cellulose, resins, proteins, gelatinized starch, gums, cyclodextrins, chitosan, liposomes, ammonium hydroxide, sodium hydroxide, potassium hydroxide, magnesium hydroxide, calcium hydroxide, triethylamine, diethylamine, trimethylamine, methylamine, dimethylamine, isopropylamine, triethanolamine, di- ethanolamine, disodium monohydrogen phosphate
  • one or more taste masking ex- cipients such as flavors, sweeteners, acidic amino acids, lipids, and surfactants can be used.
  • Another embodiment of the present invention provides a carbohydrate-based fast dissolving dosage form.
  • Co-processed carbohydrates can be used in embodiments.
  • one or more sugar - based excipients may be used. These excipients are, but not limited to, amylose, dextrose, fructose, sucrose,maltose, erythritol, isomalt, lacitol, maltitol, mannitol, sorbitol, starch hydrolysate, polydextrose, glucose, xylitol, mixtures thereof and the like.
  • inert solid ingredients that volatize readily are, but not limited to, urea, ammonium bicarbonate, ammonium carbonate, hexamethylene tetramine, naphthalene, phthalic anhydride, benzoic acid, camphor, menthol, mixtures of thereof and the like.
  • any method can be used such as, but not limited to, extrusion, film coating, casting and the like.
  • the film-forming agents are but not limited to, pullulan, hydroxypropylmethyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, polyvinyl pyrrolidone, car- boxymethyl cellulose, polyvinyl alcohol, sodium alginate, polyethylene glycol, xanthan gum, tragacanth gum, guar gum, acacia gum, arabic gum, locust bean gum, polyacrylic acid, methylmethacrylate copolymer, carboxyvinyl polymer, amylose, high amylose starch, hydroxypropylated high amylose starch, dextrin, pectin, chitin, chitosan, levan, elsinan, collagen, gelatin, zein, gluten, soy protein isolate,whey protein isolate, casein, mixtures thereof and
  • Tablet molding excipients are, but not limited to polyvinyl alcohol, methylcellulose, hydroxyethyl cellulose, hydroxypropyl cellulose , hydroxypropyl starch, starch , mixtures thereof and the like.
  • Fast disintegrating or fast dissolving pharmaceutical formulations may be prepared by different methods as below;
  • active pharmaceutical ingredients may be granulated seperately and then granulates may be assemblied namely the active pharmaceutical ingredients are each dispersed within its own pharmaceutically acceptable carrier .
  • One of them may be direct compression (DC) form.
  • One active pharmaceutical ingredient may be granulated and then granulated active pharmaceutical ingredient may be assemblied with non granulated active pharmaceutical ingredient
  • One active pharmaceutical ingredient may be dissolved alone or with one or more excipient and then other active pharmaceutical ingredient alone or with one or more excipients may be coated with said solution
  • One active pharmaceutical ingredient may be dispersed alone or with one or more excipient and then other active pharmaceutical ingredient alone or with one or more excipient may be coated with said dispersion
  • a bilayer pharmaceutical tablet comprising a first layer containing dimenhydrinate and a second layer containing cinnarizine or vice versa .
  • a tablet-in-tablet composition comprising: a) a core tablet
  • a compressed outer tablet layer comprising cinnarizine or vice versa .

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention a pour objet des formes posologiques de combinaison de cinnarizine et de diménhydrinate à dissolution rapide ou à désintégration rapide.
PCT/IB2009/053702 2009-08-24 2009-08-24 Formes posologiques de combinaison de cinnarizine et de diménhydrinate à désintégration rapide WO2011024029A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/IB2009/053702 WO2011024029A1 (fr) 2009-08-24 2009-08-24 Formes posologiques de combinaison de cinnarizine et de diménhydrinate à désintégration rapide

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2009/053702 WO2011024029A1 (fr) 2009-08-24 2009-08-24 Formes posologiques de combinaison de cinnarizine et de diménhydrinate à désintégration rapide

Publications (1)

Publication Number Publication Date
WO2011024029A1 true WO2011024029A1 (fr) 2011-03-03

Family

ID=42110930

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2009/053702 WO2011024029A1 (fr) 2009-08-24 2009-08-24 Formes posologiques de combinaison de cinnarizine et de diménhydrinate à désintégration rapide

Country Status (1)

Country Link
WO (1) WO2011024029A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012175747A1 (fr) * 2011-06-24 2012-12-27 Hennig Arzneimittel Gmbh & Co. Kg Procédé de production et forme galénique
WO2013060343A1 (fr) * 2011-10-25 2013-05-02 Expermed S.A. Composition pharmaceutique sublinguale contenant un antihistaminique et procédé de préparation associé
WO2014001268A1 (fr) * 2012-06-25 2014-01-03 Hennig Arzneimittel Gmbh & Co. Kg Forme galénique pour la libération prolongée de substances actives
CN108578378A (zh) * 2018-07-25 2018-09-28 江苏黄河药业股份有限公司 一种茶苯海明口腔崩解片及其制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060135533A1 (en) * 2003-01-15 2006-06-22 Helga Schleenhain Compound preparation for dizziness
US20090175941A1 (en) * 2005-03-23 2009-07-09 Gernot Francas Tablet-form slow-release preparation for vertigo

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060135533A1 (en) * 2003-01-15 2006-06-22 Helga Schleenhain Compound preparation for dizziness
US20090175941A1 (en) * 2005-03-23 2009-07-09 Gernot Francas Tablet-form slow-release preparation for vertigo

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
GOLDING ET AL: "Motion sickness susceptibility", AUTONOMIC NEUROSCIENCE: BASIC AND CLINICAL, ELSEVIER, AMSTERDAM, NL LNKD- DOI:10.1016/J.AUTNEU.2006.07.019, vol. 129, no. 1-2, 30 October 2006 (2006-10-30), pages 67 - 76, XP024972707, ISSN: 1566-0702, [retrieved on 20061030] *

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012175747A1 (fr) * 2011-06-24 2012-12-27 Hennig Arzneimittel Gmbh & Co. Kg Procédé de production et forme galénique
WO2013060343A1 (fr) * 2011-10-25 2013-05-02 Expermed S.A. Composition pharmaceutique sublinguale contenant un antihistaminique et procédé de préparation associé
AU2011379627B2 (en) * 2011-10-25 2015-09-10 Expermed S.A. Sublingual pharmaceutical composition containing an antihistamine agent and method for the preparation thereof
US9675551B2 (en) 2011-10-25 2017-06-13 Expermed S.A. Sublingual pharmaceutical composition containing an antihistamine agent and method for the preparation thereof
WO2014001268A1 (fr) * 2012-06-25 2014-01-03 Hennig Arzneimittel Gmbh & Co. Kg Forme galénique pour la libération prolongée de substances actives
KR20150041612A (ko) * 2012-06-25 2015-04-16 헨니그 아르쯔나이미텔 게엠베하 운트 코. 카게 활성 물질의 연장된 방출을 위한 약제학적 형태
EA028064B1 (ru) * 2012-06-25 2017-10-31 Хенниг Арцнаймиттель Гмбх Унд Ко. Кг Лекарственная форма для продленного высвобождения действующих веществ
EA035815B1 (ru) * 2012-06-25 2020-08-14 Хенниг Арцнаймиттель Гмбх Унд Ко. Кг Лекарственная форма в форме слоистой таблетки, способ её изготовления и её применение для лечения головокружения
KR102160837B1 (ko) 2012-06-25 2020-09-29 헨니그 아르쯔나이미텔 게엠베하 운트 코. 카게 활성 물질의 연장된 방출을 위한 약제학적 형태
CN108578378A (zh) * 2018-07-25 2018-09-28 江苏黄河药业股份有限公司 一种茶苯海明口腔崩解片及其制备方法

Similar Documents

Publication Publication Date Title
CA2585363C (fr) Compositions pharmaceutiques au gout masque preparees par coacervation
ES2462536T3 (es) Comprimido orodispersable multicapa
ES2645255T3 (es) Comprimidos orodispersables
US20060057207A1 (en) Fast-disintegrating dosage forms of 5,8,14-triazatetracyclo[10.3.1.02,11.04,9]-hexadeca-2(11),3,5,7,9-pentaene
EP1631263B1 (fr) Comprime orodispersible multicouche
WO2007074472A2 (fr) Composition pharmaceutique se dissolvant dans la bouche et son procede de preparation
CA2593432A1 (fr) Formes posologiques a desintegration rapide de 5,8,14-triazatetracyclo[10.3.1.02,11.04,9]-hexadeca-2(11),3,5,7,9-pentaene
WO2011048563A2 (fr) Comprimés de bétahistine fondant dans la bouche
WO2014127786A1 (fr) Composition pharmaceutique à désintégration orale comprenant de l'asénapine
EA013211B1 (ru) Быстрораспадающаяся диспергирующаяся во рту лекарственная форма и способ ее приготовления
WO2011024029A1 (fr) Formes posologiques de combinaison de cinnarizine et de diménhydrinate à désintégration rapide
JP6164346B2 (ja) 口腔内崩壊錠の製造方法
KR20070118247A (ko) 쓴맛이 저감된 프란루카스트 수화물을 함유하는 제제
EP1469848B1 (fr) Formulations de non-benzodiazepine sedative
WO2019151964A2 (fr) Formulations de saxagliptine à délitement buccal
WO2023067620A1 (fr) Compositions pharmaceutiques de rivaroxaban à désintégration orale
US20030165566A1 (en) Sedative non-benzodiazepine formulations
Patil et al. Recent trends and formulation technology of orodispersible tablets
EP2959889A1 (fr) Formulations de loxoprofen se désintégrant par voie orale
EP2962685B1 (fr) Formulations de tadalafil se désintégrant par voie orale
Dharwal et al. Orally disintegrating tablets: A complete review on methodology
WO2013098399A1 (fr) Formulation de mozavaptan
WO2011048557A1 (fr) Comprimés à délitement oral de mémantine
Kumar et al. Fast dissolving drug delivery system: Innovative strategies for drug application
WO2013098406A1 (fr) Formulations d'éprotirome

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09787000

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2012/06091

Country of ref document: TR

122 Ep: pct application non-entry in european phase

Ref document number: 09787000

Country of ref document: EP

Kind code of ref document: A1